Innovative Approaches by Affini-T Therapeutics in Oncogenic Treatments
Affini-T Therapeutics, a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies for cancer, is making significant strides in its mission to address solid tumors driven by oncogenic mutations. The company recently announced plans to present critical data regarding its various programs targeting mutations such as TP53 R175H, KRAS G12D, and KRAS G12V at a prominent meeting dedicated to cancer research.
Presentations at the Society for Immunotherapy of Cancer Annual Meeting
During the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, Affini-T is set to showcase a Trial-In-Progress poster part of its Phase 1 clinical trial assessing AFNT-211, specifically designed to target KRAS G12V mutation which has been notoriously difficult to treat. In addition, the team plans to present preclinical data concerning their innovative non-viral TRAC-knocked-in T cell therapies aimed at the TP53 R175H mutation and bi-specific T cell engagers that promise to engage multiple oncogenic targets including KRAS G12D and KRAS G12V mutations.
Details on the Sessions
One of the key posters titled "A Phase 1 Study of Autologous CD4+ and CD8+ T Cells, HLA-A*11:01-restricted, KRAS G12V-specific, Transgenic TCR" will highlight the advances and statistical results of their Phase 1 trial, which is vital for understanding the safety and efficacy of their therapies. Several other posters showcasing further applications of their innovative T cell therapies will also be available for discussion, making this a notable event for oncologists and immunotherapy researchers alike.
The Vision Behind Affini-T’s Innovations
Dirk Nagorsen, Chief Medical Officer at Affini-T Therapeutics, emphasized their strategy to utilize precision immunotherapy specifically designed to tackle cancers with significant genetic mutations. The company aims to provide advanced therapeutic solutions that directly target the root causes of these cancers. The commitment to improving patient lives by focusing on driver mutations is central to Affini-T’s philosophy in this innovative space.
Utilizing Cutting-Edge Platforms and Technologies
Affini-T has developed their proprietary THRIVE™ platform, which focuses on efficient and effective engineering of T cell therapies. This technology is not just a concept but a tangible solution that allows for the creation of T cell products intended to be safe for patients while maintaining high effectiveness in attacking tumors.
Transforming Oncology with Latest Innovative Therapies
Moreover, the company plans to introduce groundbreaking data regarding their T cell engagers, targeting both TP53 and KRAS mutations, which are common in various malignant solid tumors. By leveraging their TETHER™ platform, which stands out for its versatility, Affini-T is paving the way for combinations of cutting-edge treatments.
AFNT-211: Pioneering Efforts in Clinical Trials
One of the most anticipated therapies, AFNT-211, is an investigational autologous T cell therapy newly made available to patients. It is designed to engage specifically with the KRAS G12V mutation, a pivotal target in modern cancer treatment. The ongoing Phase 1 clinical trial makes it a significant focus for both the Affini-T team and industry observers eager to witness advancements in targeted therapy.
About Affini-T Therapeutics
Established as a leader in precision immunotherapy, Affini-T Therapeutics focuses on developing life-altering treatments for patients battling solid tumors. With their advanced T Cell Receptor (TCR) based approaches including adoptive cellular therapies and bispecific T cell engagers, their goal is to maximize T cell immunity strategically and safely. The approach is grounded on years of research and innovative techniques that challenge conventional methods in cancer therapy.
Frequently Asked Questions
What is AFNT-211?
AFNT-211 is an autologous T cell therapy designed to target the KRAS G12V mutation in patients with solid tumors.
At which event will Affini-T present their findings?
Affini-T Therapeutics will present data at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
What are the primary targets of Affini-T’s therapies?
The main targets of their therapies are mutations such as TP53 R175H, KRAS G12D, and KRAS G12V.
How does Affini-T’s THRIVE™ platform work?
THRIVE™ is a gene-targeted knock-in platform designed to engineer safe and effective T cell therapy products.
What is the goal of Affini-T Therapeutics?
The goal is to address unmet needs in patients with solid tumors by developing innovative precision immunotherapies.
